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Abstract
Suboptimal sleep causes cognitive decline and probably accelerates Alzheimer's 
Disease (AD) progression. Several sleep interventions have been tested in estab-
lished AD dementia cases. However early intervention is needed in the course of AD 
at	Mild	Cognitive	Impairment	(MCI)	or	mild	dementia	stages	to	help	prevent	decline	
and maintain good quality of life. This systematic review aims to summarize evidence 
on	sleep	interventions	in	MCI	and	mild	AD	dementia.	Seven	databases	were	system-
atically	 searched	 for	 interventional	 studies	where	≥	75%	of	participants	met	diag-
nostic	criteria	for	MCI/mild	AD	dementia,	with	a	control	group	and	validated	sleep	
outcome measures. Studies with a majority of participants diagnosed with Moderate 
to Severe AD were excluded. After removal of duplicates, 22,133 references were 
returned in two separate searches (August 2019 and September 2020). 325 full pa-
pers	were	reviewed	with	18	retained.	Included	papers	reported	16	separate	studies,	
total sample (n =	1,056),	mean	age	73.5	years.	13	interventions	were	represented:	
Cognitive	 Behavioural	 Therapy	 –	 Insomnia	 (CBT-I),	 A	 Multi-Component	 Group	
Based Therapy, A Structured Limbs Exercise Programme, Aromatherapy, Phase 
Locked Loop Acoustic Stimulation, Transcranial Stimulation, Suvorexant, Melatonin, 
Donepezil,	 Galantamine,	 Rivastigmine,	 Tetrahydroaminoacridine	 and	 Continuous	
Positive Airway Pressure (CPAP). Psychotherapeutic approaches utilising adapted 
CBT-I	 and	a	Structured	Limbs	Exercise	Programme	each	achieved	 statistically	 sig-
nificant	improvements	in	the	Pittsburgh	Sleep	Quality	Index	with	one	study	report-
ing co-existent improved actigraphy variables. Suvorexant significantly increased 
Total	Sleep	Time	and	Sleep	Efficiency	whilst	reducing	Wake	After	Sleep	Onset	time.	
Transcranial Stimulation enhanced cortical slow oscillations and spindle power during 
daytime naps. Melatonin significantly reduced sleep latency in two small studies and 
sleep to wakefulness transitions in a small sample. CPAP demonstrated efficacy in 
participants	with	Obstructive	Sleep	Apnoea.	Evidence	to	support	other	interventions	
was limited. Whilst new evidence is emerging, there remains a paucity of evidence for 
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1  | INTRODUC TION
The association between Alzheimer's Disease [AD] and sleep dis-
turbance is well established (Mander, 2013; Tranah et al., 2011). 
The traditional view has been that AD causes sleep impairment and 
the extent of symptomatic sleep disturbance correlates with the 
severity of dementia (Benca et al., 1992; Montplaisir et al., 1995; 
Pat-Horenczyk et al., 1998; Prinz et al., 1982; Weldemichael & 
Grossberg,	 2010).	 Circadian	 rhythm	 disorders	 also	 contribute	 to	
sleep disturbance and worsen with age and AD, possibly related to 
alterations to the Suprachiasmatic Nucleus secretion of melatonin 
(Swaab et al., 1985).
A recent prominent theory postulates a bidirectional relation-
ship between poor sleep and AD (Mander et al., 2016) – as well as 
AD causing sleep disturbance, sleep disturbance may lead directly 
to pathological accumulation of proteins that cause neurodegenera-
tion	(Fultz	et	al.,	2019;	Hahn	et	al.,	2014).	Beta	amyloid	is	one	of	the	
two pathognomonic changes of AD. Levels of soluble Amyloid Beta 
fluctuate diurnally in both mice and humans showing the crucial role 
that sleep plays in its clearance (Huang et al., 2012). Amyloid Beta 
42	levels	have	been	shown	to	be	significantly	increased	after	a	sin-
gle	night	of	sleep	deprivation	in	healthy	adults	(Ooms	et	al.,	2014)	
and slow oscillations are temporally linked to CSF flow (Fultz 
et al., 2019). Chronic sleep deprivation accelerates accumulation of 
soluble beta amyloid into insoluble amyloid plaques in two mouse 
models (Kang et al., 2009). A cascade is envisaged in which poor 
sleep disrupts the clearance of soluble amyloid, leading to plaque 
deposition. This precipitates further plaque formation through rec-
ognised positive feedback loops (Mandrekar-Colucci et al., 2012). 
Regardless of whether sleep disturbance arises directly from accu-
mulation of AD pathology or through an independent problem such 
as	 sleep	 apnoea	 (Ancoli-Israel,	 2000;	 Bliwise,	 1999;	 Van	 Cauter	
et al., 2000), poor sleep might be a significant contributory factor in 
the eventual onset and progression of AD.
AD pathology progresses for 1–2 decades before a full dementia 
diagnosis giving plenty of time for factors such as sleep disturbance to 
affect the rate of pathological progression (Jack et al., 2010). Therefore, 
the optimal opportunity to reverse or halt cognitive decline caused 
by AD pathology, thus maintaining quality of life, will be early in the 
course	of	disease	–	at	the	Mild	Cognitive	Impairment	or	mild	AD	stage.	
Early diagnosis utilising molecular biomarkers to accurately pinpoint 
the cause of cognitive symptoms is becoming more common, most fre-
quently	for	identification	of	early/prodromal	AD	(Sutphen	et	al.,	2014)	
and this provides an opportunity for targeted intervention.
Disruption of sleep occurs early in AD (Ju et al., 2013; Lim 
et	 al.,	 2013;	 Sprecher	 et	 al.,	 2017),	 even	 before	 symptoms	 arise,	
however, the focus of sleep intervention reviews to date have largely 
been at the stage of established AD dementia (Mitolo et al., 2018; 
O'Caoimh	 et	 al.,	 2019)	 when	 pathology	 may	 be	 too	 advanced	 to	
change. Sleep disorders are also common in this population affect-
ing	up	to	60%	of	patients	 in	memory	clinics	 (Littlejohn	et	al.,	2014).	
Furthermore, sleep deprivation brings a range of other metabolic and 
cardiovascular impairments that mean improving sleep is likely to be 
broadly beneficial in the memory clinic population over and above the 
potential to modify progression of AD. However, there are no stan-
dard sleep treatment protocols within memory clinics and other de-
mentia services.
There are multiple theoretical targets for sleep enhancement in AD 
(summarised in Figure 1). Much of the previous literature has focussed 
on pharmacological interventions (McCleery et al., 2016). Notable disad-
vantages of this approach, particularly in older adults, include the poten-
tial	for	side	effects,	interactions	and	polypharmacy	(Maher	et	al.,	2014).	
Hence, interest in non-pharmacological sleep-modifiers is intensifying 
with recent technological advances permitting exploration of novel ap-
proaches such as closed loop stimulation of slow wave sleep through 
sound or electrical brain stimulation (Ngo et al., 2013) and glasses to de-
liver	Bright	Light	Therapy	(Sekiguchi	et	al.,	2017).	Lifestyle	interventions	
are often cost effective and non-toxic and have the potential to enhance 
sleep in early stages of AD, but have not previously been the focus of re-
views	in	mild	AD	and	MCI.	We	include	all	potential	types	of	intervention,	
including lifestyle interventions, in the searches for this review.
Here we systematically review the literature on sleep inter-
ventions for people meeting established criteria for either Mild 
Alzheimer's	Disease	or	Mild	Cognitive	 Impairment.	We	 focus	 spe-
cifically on AD rather than other subtypes of dementia as there are 
specific	mechanisms	proposed	to	link	sleep	disturbance	to	AD.	In	the	
absence of trials of sufficient length or size to establish the efficacy 
of sleep disturbance treatment on AD disease progression, we first 
review studies that measure the effect of intervention on sleep as an 
initial step in the translational pathway to slowing AD progression. 
This review does not explore the effect of interventions on specific 
sleep	 phenotypes	 due	 to	 the	 paucity	 of	 data.	 Improving	 sleep	 re-
gardless of presence or absence of sleep disorder could plausibly 
impact on AD. Therefore inclusion and exclusion of any underlying 
sleep disorders in study design was noted, permitted and discussed.
In	order	to	assess	the	degree	to	which	different	avenues	for	treat-
ing sleep in early AD have been explored, we, a priori, created a logic 
model to incorporate different possible intervention targets (Figure 1). 
We then compare the scope of existing studies with the model to guide 
where gaps might lie. The 9 targets included; promotion of wakefulness 
(to build sleep pressure), optimising circadian fluctuations, improving 
bed time routines (to remove barriers to sleep), removing overnight 
sleep	interventions	in	MCI	and	mild	AD	highlighting	a	pressing	need	for	high	quality	
experimental studies exploring alternative sleep interventions.
K E Y W O R D S
AD,	Alzheimer's	dementia,	Alzheimer's	disease,	MCI,	mild	cognitive	impairment,	sleep
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environmental barriers to sleep, enhancing Non-Randomised Eye 
Movement (NREM) sleep, improving REM sleep, treating psychological 
causes of insomnia, optimising day time behaviour to promote sleep at 
night and treating comorbidities that interrupt sleep.
2  | METHODS
The review followed recommendations by the Preferred Reporting 
Items	 for	 Systematic	 Review	 and	 Meta-Analyses	 Statement	
(PRISMA)	 (Moher	et	al.,	2009).	The	protocol	was	 registered	 in	 the	
Prospero	Database	(registration	number	CRD42019126320).
2.1 | Eligibility criteria
All peer reviewed articles written in English were eligible for inclu-
sion. The following criteria were used:
2.1.1 | Participants
Inclusion	criteria:
1. Adults aged greater than 18 (limit set to avoid excluding 
studies in genetic dementias); and
2. Male or Female; and
3.	 At	least	75%	of	the	studied	group	meet	the	following	criteria:
Exclusion criteria:
a.	 Satisfies	 established	 diagnostic	 criteria	 for	MCI	 e.g.	 Albert	
Criteria (Albert et al., 2011), Peterson Criteria (Petersen 
et al., 1999) or would be expected to meet these criteria if 
the study was conducted before 1999.
Or:
b. Satisfies established diagnostic criteria for AD demen-
tia	 e.g.	 DSM-IV	 (American	 Psychiatric	Association,	 2000),	
DSM-V	 (American	 Psychiatric	 Association,	 2013),	 ICD-
10	 (World	 Health	 Organization,	 2004),	 ICD-11	 (World	




ies where a majority of the studied group is likely to 
have Moderate to Severe AD dementia as evidenced by:
a. Mini Mental State Examination (MMSE) less than 20;
Or:
b. Clinical Dementia Rating (CDR) greater than or equal to 2;
Or:
c. Equivalent measure.
F I G U R E  1   Theoretical interventional strategies to enhance sleep in people developing Alzheimer's disease
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2.1.2 | Exposure
Interventions	of	 interest	 include	any	pharmacological	or	non-phar-
macological treatment/technique primarily utilised to improve the 
duration or quality of sleep.
2.1.3 | Comparator
The studied intervention must be compared with at least one other 
intervention, non-exposure or placebo.
2.1.4 | Outcome
Sleep outcomes e.g. total sleep time, sleep efficiency or sleep 
latency measured by an appropriate validated sleep outcome 
measure.
2.1.5 | Study design
Eligible studies included comparison study designs e.g. ran-
domised controlled trials (RCTs), group trial designs, case-control, 
cross-sectional and prospective cohort studies as well as multiple 
base studies. Systematic reviews and meta-analyses were refer-
ence tracked. Case reports, abstracts and grey literature were 
excluded.
2.2 | Search strategy
Medical Subject Headings (MeSH) index terms were used together 
with free text to capture relevant results. Preliminary research was 
undertaken to identify relevant synonymous terminology and re-
fine the search strategy. The full list of search terms is provided in 





ditional studies. The search was undertaken on 19th August 2019 and 
repeated on 8th September 2020.
2.3 | Study selection
Search results were merged using reference management software 
and	duplicate	records	of	the	same	report	removed.	A	sample	of	10%	
of the total titles were reviewed by each reviewing team member 
to ensure consensus in decision making. Remaining titles were re-
viewed individually by a member of the reviewing team in order to 
exclude studies obviously not meeting criteria.
Abstracts of the retained references were examined against in-
clusion	and	exclusion	criteria	with	a	further	sample	of	10%	reviewed	
by each reviewing team member to ensure consensus. The full texts 
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a2 separate papers written by Cassidy-Eagle reporting data from the same study. Analysis was focussed on paper reporting sleep outcome measures  
in more detail to avoid over-representation of data. Quality appraisal and risk of bias assessment identical due to same study design. 
b2 separate papers written by Cruz-Aguilar reporting data from the same study. Analysis focussed on combined findings. Quality appraisal and risk of  
bias assessment identical due to same study design. 
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the reference lists of any identified relevant review articles were 
hand searched to ensure capture of references not identified on the 
electronic databases.
Retained studies were recorded in a spreadsheet and included 
study characteristics, details of the patient/population group, inter-
vention and primary outcomes. Where required, correspondence with 
investigators was attempted in order to gain further study data or to 
clarify study eligibility. Discrepancies were resolved through discus-
sion with the first author (JB) in consensus with the reviewing team.
2.4 | Data extraction
Data extracted from the retained articles (Table 1) included: 
Participant Characteristics (No. of participants, country, gen-
der, age), Condition/Diagnosis, Sleep Co-Morbidity, Study Type, 
Intervention(s)	 Studied,	 Intervention	 Dosage/Duration,	 Control	
Group,	 Validated	 Outcome	 Measure	 Used,	 Sleep	 Parameters	
Measured, Data on Efficacy, Data on Complications.
2.5 | Quality assessment
Methodological quality of eligible studies was evaluated using 
the	 Joanna	 Briggs	 Institute	 Checklist	 for	 Quasi-Experimental	 and	
Randomized	Controlled	Trials	 (Tufanaru	et	 al.,	 2017).	 Independent	
evaluation of quality was undertaken by two reviewers (SH and JB) 
and consensus reached jointly.
Risk of bias for all included studies was also assessed using the 
Cochrane Collaboration's Tool for Assessing Risk of Bias (Higgins 
et al., 2019). Two reviewers (SH and JB) undertook this analysis inde-
pendently before reaching joint consensus.
2.6 | Data synthesis and analysis
Due to substantial heterogeneity in outcome measures no meta-
analysis of quantitative data was appropriate. Therefore a narrative 
synthesis of included studies was performed focusing on population 
characteristics, interventions utilised and outcomes. The main focus 
of analysis was on the performance of the intervention assessed 





and subsequently 325 full text articles were screened for eligibility 
with a total of 18 articles selected for inclusion which were pub-
lished	between	1998	and	2020	(see	PRISMA	flowchart	–	Figure	2).	
There were two predominant reasons for exclusion, (a) ineligible 
study type e.g. intervention not analysed against an alternative or 
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a2 separate papers written by Cassidy-Eagle reporting data from the same study. Analysis was focussed on paper reporting sleep outcome measures  
in more detail to avoid over-representation of data. Quality appraisal and risk of bias assessment identical due to same study design. 
b2 separate papers written by Cruz-Aguilar reporting data from the same study. Analysis focussed on combined findings. Quality appraisal and risk of  
bias assessment identical due to same study design. 
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F I G U R E  2  PRISMA	flowchart
Abstracts assessed for eligibility
(n = 790)
Records excluded at Title Review Stage
(n = 21343)








• WHO ICTRP: 42
(n = 27609)
Records excluded at Abstract Review Stage
(n = 465)
Records after duplicates removed
(n = 22133)
Records identified through bibliographic search
(n = 44)
Studies included in synthesis
(n = 18)
Full texts screened for eligibility
(n = 325)
Full text articles excluded, with rationale:
• Review Articles = 16
• Excluded Study Type = 81
• Ineligible Population = 103
• No Control Group = 9
• Inadequate Outcome Measures = 19
• Full Text Not Available = 34
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Mayo Clinic Criteria (n = 1)
Assessment of Dementia 
Severity Tool
MMSE (n = 10)
MoCA (n = 2)
CDR (n = 2)
TDAS (n = 1)
Not reported (n = 1)a 
Baseline Cognitive Scores 
by Tool
Mean MMSE 22.38/30 (n = 9)
Median MMSE 28/30 (n = 1)
Mean	MOCA	21.93/30	(n = 2)
Mean CDR 1.38 (n = 2)
Mean	TDAS	7.57	(n = 1)
Sleep Co-Morbidity Status Sleep	Disorders	Included:-
• Mixed Population ± Sleep Disorder (n = 5)
•	 OSA	(n = 2)
•	 Insomnia	by	DSM	V	Criteria	(n = 2)
• Clinically determined ‘Alteration to Sleep Pattern’ (n = 1)
Sleep Disorders Excluded:-
• All (n = 2)
• Self-Reported Sleep-Wake Disturbance (n = 1)
• Moderate-Severe Sleep Disturbance (n = 1)
•	 Circadian	Rhythm	Disorders	and	OSA	(n = 1)
• Significantly Reduced SWS (n = 1)
Comparison
Methodology Used Placebo	Groups	(n =	4)
Active	Non-Pharmacological	Control	Groups	(n = 3)
Non-Treatment Arms (n = 2)
Placebo Crossover Designs (n = 5)
Healthy	Population	Group	(n = 1)
Multiple Treatment Arms (n = 1)
Outcome
Measurement Tools Polysomnography (n = 8)
Wrist Actigraphy (n =	4)
PSQI	(n = 6)





TST (Polysomnography n = 6, Actigraphy n =	3,	PSQI	n = 2)
SE (Polysomnography n = 6, Actigraphy n =	3,	PSQI	n = 2)
WASO	(Polysomnography	n = 5, Actigraphy n = 3)






Characteristics and REM Characteristics (Polysomnography 
n =	4)
aDiagnosis	of	MCI	made	utilising	peterson	criteria.	
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The 18 articles identified reported on data from 16 separate stud-
ies. Attributes of individual included studies are listed in Table 1.
3.2 | Participants and comparison measures
A summary of combined included study characteristics is shown in 
Table 2.
3.3 | Outcome measurement and outcomes
As per Table 2, studies utilised a wide range of measurement tools 
with broad and heterogeneous primary and secondary outcome 
measures.
Directly comparable group data across key outcome measures 
was	relatively	sparse.	Only	8	studies	reported	TST	in	minutes,	one	
reporting	data	from	afternoon	naps	and	hence	not	comparable.	SE	%	
was similarly provided in only 8 studies comprising 220 participants 
in	intervention	groups	and	214	participants	in	control	groups	across	
five	studies	and	for	27	patients	in	crossover	designs	over	three	stud-
ies. Surrogate measures of TST and SE were provided by two studies 
utilising	PSQI	in	162	intervention	participants	and	121	control	par-
ticipants and 159 intervention participants and 115 control partic-
ipants	respectively.	Structural	sleep	%	by	stage	N1,N2,N3/N4	and	
REM group means were provided in 250 participants in intervention 
groups and 198 in control groups across four studies and in 25 par-
ticipants	across	3	crossover	studies.	Actual	Total	PSQI	Scores	were	
provided	 in	 284	 intervention	 participants	 and	 207	 control	 groups	
across five studies.
3.4 | Adverse events
These were described in three studies. Herring et al. (2020) reported 
22.5%	of	participants	taking	Suvorexant	experiencing	adverse	events	
compared	with	16.1%	of	participants	in	the	placebo	group.	One	serious	
adverse event (fall sustaining ankle fracture), judged non-drug related, 
was reported in the Suvorexant group resulting in drug discontinua-
tion	with	somnolence	the	most	commonly	reported	side	effect,	4.2%	
versus	 1.4%	 (Suvorexant	Group	 vs.	 Placebo	Group).	Donepezil	was	
reported by Moraes et al. (2006) to cause mild and transitory side ef-
fects including headache and nausea in 3 patients in an intervention of 
group	of	17.	Kouzuki	et	al.	(2020)	reported	minor	dermatological	side	
effects following the use of bath salts. No significant adverse events 
were reported across the remaining included studies.
3.5 | Quality appraisal and risk of bias
Quality appraisal was undertaken independently by two reviewers 
(JB	 and	 SH).	 Inter-rater	 reliability	 calculated	 using	 Cohen's	 Kappa	
Coefficient	was	0.807	[95%	CI	0.715–0.900]	indicating	strength	of	
agreement to be ‘substantial’. For full tabulated results see Figures 3-
5. The overall quality of included studies as measured by the appro-
priate Joanna Briggs Quality Appraisal Tool was variable. Multiple 



























































































































































1 Was true randomisation used for assignment of participants to treatment groups?
2 Was allocation to treatment groups concealed?
3 Is it clear in the study what is the 'cause' and what is the 'effect'?
4 Were treatment groups/participants similar at the baseline?
5 Were participants blind to treatment assignment?
6 Were those delivering treatment blind to treatment assignment?
7 Were outcome assessors blind to treatment assignment?
8 Were treatment groups treated identically other than the intervention of interest?
9 Was there a control group?
10 Were there multiple outcome measurements?
11 Was follow-up complete or differences adequately described/analysed?
12 Were participants analyzed in the groups to which they were randomised?
13 Were outcomes measured in the same way for treatment/participant groups?
14 Were outcomes measured in a reliable way?
15 Was appropriate statistical analysis used?
16 Was the trial design appropriate with deviations accounted for?
No
Not Applicable
Items 1,2,4,5,6,7,8,11,12,13,14,15,16 from JBI - Randomised Controlled Trial Toolkit
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limitations were identified in one study (Cruz-Aguilar et al., 2018), 
however this was partly due to inherent difficulties in conceal-
ment and blinding associated with utilising a psychotherapeutic 
intervention.	One	further	study	had	3	limitations	identified	(Cooke	
et al., 2006), three studies had two limitations identified (Naismith 
et al., 2018; Petit et al., 1993; Wang et al., 2020). The remaining 
eleven studies had 0 or 1 limitation.




bias in at least one area was identified in eight included studies with 
five	identified	as	being	at	‘high	risk’	in	multiple	domains.	Information	
regarding group randomisation and blinding was particularly scarce 
in the majority of studies with only one (Herring et al., 2020) clearly 
demonstrating low risk in all domains. For full results see Figure 6.
3.6 | Summary of interventions
Overall	we	 found	 trials	 in	 seven	of	 the	nine	 intervention	domains	
identified	 in	Figure	1.	Only	one	was	a	 large	randomised	controlled	
trials powered to find clinical benefit. Most were exploratory, pilot 
or feasibility trials. There was an over-representation of trials that 
used cholinesterase inhibitors to enhance sleep and there were no 
trials that aimed to promote wakefulness, optimise bedtime routines 
F I G U R E  4  Overall	quality	appraisal	by	Joanna	Briggs	Institute	-	Quasi	experimental	tool
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Is it clear in the study what is the 'cause' and what is the 'effect'?
Were treatment groups/participants similar at the baseline?
Were treatment groups treated identically other than the intervention of…
Was there a control group?
Were there multiple outcome measurements?
Was follow-up complete or differences adequately described/analysed?
Were outcomes measured in the same way for treatment/articipant groups?
Were outcomes measured in a reliable way?
Was appropriate statistical analysis used?
Yes Unclear No
F I G U R E  5  Overall	quality	appraisal	by	Joanna	Briggs	Institute	–	Randomised	controlled	trial	tool
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Was true randomisation used for assignment of participants to treatment groups?
Was allocation to treatment groups concealed?
Were treatment groups/participants similar at the baseline?
Were participants blind to treatment assignment?
Were those delivering treatment blind to treatment assignment?
Were outcome assessors blind to treatment assignment?
Were treatment groups treated identically other than the intervention of interest?
Was follow-up complete or differences adequately described/analysed?
Were participants analyzed in the groups to which they were randomised?
Were outcomes measured in the same way for treatment/participant groups?
Were outcomes measured in a reliable way?
Was appropriate statistical analysis used?
Was the trial design appropriate with deviations accounted for?
Yes Unclear No
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or remove environmental barriers to sleep. Results of individual trials 
within each potential intervention domain are as follows:
3.6.1 | Enhancing REM
Donepezil
Cooke et al. (2006) compared donepezil against galantamine, ri-
vastigmine	and	a	group	 taking	no	Acetylcholine	Esterase	 Inhibitor	
(AChEI).	 Participants	had	no	prior	 sleep	disorder	 and	 analysis	was	
undertaken	 to	 test	 the	 hypothesis	 that	AchEIs	may	 increase	REM	
sleep and nightmares. Polysomnographic analysis showed a signifi-
cant	decrease	in	Stage	I	sleep	(p = .01) and for those taking donepezil 
compared to those taking galantamine but no changes compared to 
other	groups.	There	was	also	a	significant	increase	in	Stage	II	sleep	
(p =	.04)	compared	to	the	group	taking	no	AChEI.
However this finding was not replicated when Moraes 
et al. (2006) tested a similar hypothesis that Donepezil may increase 
REM	 sleep	 percentage	 and	 alter	 the	 REM	 sleep	 EEG	 power	 spec-
trum. Donepezil was directly compared against placebo in a ran-
domized controlled trial of 35 participants with mild to moderate AD 
and without moderate or severe sleep disorders. No significant dif-
ferences were found polysomnographically between donepezil and 
placebo for TST, SE, SL, REM SL or NREM sleep stage percentages. 
Donepezil was, however, found to significantly increase REM sleep 
percentage (p < .01). Fast Fourier transformation of electroenceph-
alogram	 (EEG)	channel	data	as	part	of	REM	EEG	Spectral	Analysis	
also revealed significant decreases in overall theta band power and 
frontal delta and theta band powers after 6 months of donepezil 
compared	with	placebo	(0.01	≤	p ≤	.04).
Naharci	 et	 al.	 (2015)	 compared	 total	 PSQI	 prospectively	 in	 78	
patients	 prescribed	 Donepezil,	 Galantamine	 or	 Rivastigmine	 and	
a	control	group	not	taking	an	AChEI	with	the	rationale	to	evaluate	
the	broad	influences	of	AchEIs	on	sleep	pattern.	Study	participants	
included those with and without underlying sleep disturbance. No 
significant	change	in	total	PSQI	score	was	found	across	groups.
Galantamine
Galantamine	was	 found	to	have	 little	or	no	 impact	on	sleep	archi-
tecture by Cooke et al. (2006) in comparison with a group taking 
donepezil,	 rivastigmine	 and	 a	 group	 taking	 no	 AChEI.	 Markowitz	
et al. (2003) undertook a post-hoc analysis of a RCT comparing a 
flexible	 dose	 regime	 of	 galantamine	with	 placebo.	 It	 aimed	 to	 ex-
plore whether adverse sleep outcomes were associated with gal-
antamine both in participants with and without underlying sleep 
disorders.	 Analysis	 of	 PSQI	 and	 Neuropsychiatry	 Inventory	 Sleep	
Disorder	Items	revealed	no	significant	difference	between	groups	or	
from baseline to post intervention. However more recently Naharci 
et al. (2015) found in a non-randomised trial that galantamine when 
compared against donepezil, rivastigmine and a healthy control 
group	significantly	decreased	total	PSQI	score	(p = .028). The high-
est improvement rate was in those with reported poor sleep quality.
Rivastigmine
Rivastigmine was not associated with any change in sleep architec-
ture according to Cooke et al. (2006) although the authors acknowl-
edge that their small sample size (n = 8) is likely to have reduced the 
power to detect a significant effect. Naharci et al. (2015) also found 
that	 rivastigmine	decreased	total	PSQI	score	although	this	did	not	
reach statistical significance (p = .193).
Tetrahydroamineacridine – (Tacrine - THA)
The centrally acting anticholinesterase inhibitor THA was compared 
against placebo by Petit et al. (1993) in a small crossover trial (n = 8) 
involving participants with mild to moderate AD. THA was hypoth-
esised	to	alleviate	sleep	disturbance	in	this	group	and	restore	EEG	
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desynchronisation during wakefulness and REM sleep. There were 
no differences in sleep architecture including SE, SL, SE and percent-
ages of REM and NREM sleep on polysomnographic analysis in the 
THA	 versus	 placebo	 group.	 Spectral	 EEG	Analysis	 by	 fast	 Fourier	
transformations utilising the ratio of power in slow (delta and theta) 
frequencies to fast (alpha and beta) frequencies revealed REM sleep 
EEG	slowing	 in	 the	 frontal	 and	parietoocciptal	 regions	 in	 the	THA	
group compared to baseline (p < .01).
To summarise, included studies showed that donepezil may have 
an impact on sleep architecture through altering the relative propor-
tion of sleep stages, however the precise nature of this effect was 
not consistently demonstrated. Certainly it has not been shown to 
improve	basic	sleep	parameters	e.g.	TST,	SE	and	SL.	Galantamine	ap-
pears to have little effect on sleep architecture (Cooke et al., 2006) 
but	 may	 improve	 PSQI	 scores	 in	 a	 small	 non-randomised	 study	
(Naharci et al., 2015). Again we have found little in the way of rep-
licated findings. Rivastigmine was not demonstrated to have any 
effect on sleep (Cooke et al., 2006; Naharci et al., 2015). THA may 
reduce	EEG	REM	sleep	cortical	slowing	as	measured	by	amplitude	
spectral	EEG	analysis	(Jean-Louis	et	al.,	1998),	although	the	clinical	
relevance of this is questionable in a largely withdrawn medication 
with no demonstrable positive effects on sleep.
3.6.2 | Optimising circadian fluctuations
Melatonin
A placebo controlled crossover trial of melatonin was conducted by 
Jean-Louis	et	al.	(1998)	in	10	participants	with	MCI	and	Mild	AD	with	
self-reported sleep-wake disturbance either through difficulty in 
sleep initiation or frequent nocturnal awakenings. The study aimed 
to provide objective evidence of its effect on sleep, mood and cogni-
tion in the context of previously conflicting evidence.
Actigraphy revealed melatonin to have a statistically signifi-
cant effect on sleep latency (melatonin group =	14.7	min	[SD	7.21],	
placebo group = 26.08 min [SD	10.97],	p = .018). There was also a 
significant reduction in number of transitions from sleep to wakeful-
ness (melatonin group =	17.75	[SD	7.79],	placebo	group	= 31.20 [SD 
11.37],	p =	.011).	There	was	no	significant	effect	on	SE,	TST,	WASO	
or phase shift in rest-activity pattern.
A reduction in sleep latency was also demonstrated in a small 
pilot study of 8 participants by Cruz-Aguilar et al. (2018) utilising 
polysomnography. This single-blind placebo-controlled crossover 
study was conducted over three nights with a habituation night fol-
lowed by placebo or melatonin, subsequently reversed for the final 
night. All participants were determined to have had an ‘alteration to 
sleep pattern’ as determined by a clinical interview with a caregiver. 
Mean	sleep	latencies	reduced	from	34.75	min	[SE	8.54]	in	the	pla-
cebo group to 15.25 min [SE 2.10] in the melatonin group (p =	.04).
Suvorexant
Suvorexant	 is	 a	 potent	 dual	 orexin	 receptor	 (OX1R	 and	 OX2R)	
antagonist	 promoting	 sleep	 through	 inhibition	 of	 Orexin	 A	 and	
B, neuropeptides associated with maintenance of wakefulness. 
Previous studies including Herring et al. (2016) had demonstrated 
its efficacy in treating insomnia in healthy adults and the elderly 
population. Herring et al. (2020) assessed its performance in indi-
viduals with probable AD and insomnia in a high-quality, large ran-
domised controlled trial of 285 participants. Screening, baseline 
and post-treatment polysomnography was utilised for collection of 
the primary outcome data (TST) and secondary outcome measures 
(including	 WASO,	 SE,	 NA,	 AI	 and	 PSG	 sleep	 architectural	 meas-
ures). Subjective measures included partner-rated assessments, 
Sleep	 Disorders	 Inventory	 Total	 Score	 (Tractenberg	 et	 al.,	 2003),	
the	Neuropsychiatric	 Inventory	 (NPI)	 (Cummings	 et	 al.,	 1994),	 the	
Clinician's	Global	Impression	of	Severity	of	Patient's	Insomnia	Score	
(CGI-S)	(Busner	&	Targum,	2007).
TST increased in the Suvorexant group by an additional mean 
of	28.2	min	over	placebo	 [95%	CI	11.1–45.2],	p = .001. The num-
ber of participants with a greater than 50 min improvement in TST 
was also significantly greater in the Suvorexant group versus pla-
cebo	(62%	versus	45%,	OR	2.2	[95%	CI	1.3–3.6],	p =	 .002.	WASO	
decreased	by	45	min	in	the	Suvorexant	group,	an	additional	16	min	
when	compared	to	placebo	[95%	CI	−28	to	−3],	p < .05. This effect 
appeared particularly marked in the final third of the night with an 
additional	decrease	of	11	min	in	the	Suvorexant	group	[95%	CI	−19	to	
−3],	p = .009. SE also increased significantly in the Suvorexant group 
by	an	additional	5.7%	over	placebo	[95%	CI	2.2–9.3],	p = .002. There 
were no significant differences in other polysomnographic second-
ary	endpoints	 including	SL,	SL	REM,	NAW,	AI,	REM	and	NREM	%.	
Subjectively,	CGI-S	score	 (p = .010) and partner rating of patient's 
sleep quality (p = .021) improved nominally with no significant cor-
responding	change	in	NPI	or	SDI.
Subgroup analysis revealed that the effect of Suvorexant on TST 
was significant only in the mild (21–26) MMSE category of partic-
ipants	 (79.3%	overall)	 as	opposed	 to	 the	moderate	 (12–20)	MMSE	
category	(20.7%	overall).
3.6.3 | Enhancing NREM
Phase locked loop acoustic stimulation
Nine	participants	with	Amnestic	MCI	were	recruited	for	a	randomised	
crossover sham-controlled study conducted by Papalambros 
et al. (2019) in order to examine the feasibility of acoustic stimula-
tion during overnight sleep in enhancing Slow Wave Activity (SWA). 
Participants had no evidence of a circadian rhythm disorder or mod-
erate-severe sleep apnoea. Acoustic Stimulation was delivered as 
per a previously established protocol40 for one night on two sepa-
rate occasions seven days apart.
There were no statistically significant effects on basic sleep pa-
rameters	e.g.	TST,	SE,	SL,	WASO	or	in	sleep	staging	characteristics.	
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comparing	 Stim	OFF	with	 Sham	OFF	 of	 8.1%	 (3.3),	 p =	 .040	 and	
6.6%	 (2.9),	p =	 .046	 respectively.	Within	 the	same	night,	Stim	ON	
appeared	to	increase	SO	by	22.2%	(5.1),	p =	.003	and	SWA	by	17.9%	
(4.12),	p =	 .004	when	 compared	with	 Stim	OFF.	However	 overall,	
there was no difference in mean NREM SWA between stim and 
sham conditions. There were no statistically significant effects on 
spindle characteristics or on N2, N3 duration.
Transcranial stimulation
Ladenbauer	et	al.	(2017)	recruited	22	patients	with	MCI	to	undergo	
slow-oscillatory weak transcranial direct current stimulation (so-
tDCS) during an afternoon nap in a balanced crossover design with 
stimulation and sham condition. The study was designed to test the 
hypothesis that this may modulate cortical slow oscillations and 
thalamocortical spindle activity implicated with memory formation 
and that this may accordingly improve declarative and procedural 
memory. Stimulation electrodes were placed bilaterally at frontal 
locations	F3	and	F4	with	anodal	current	applied	by	a	battery	stimu-
lator.	 Sleep	 outcome	measures	 were	 obtained	 through	 PSG/	 EEG	
analysis.
16	 participants	 completed	 the	 full	 experiment.	 SO	 power	was	
increased in the so-tDCS group in frontal (p < .001) and centropa-
rietal (p = .006) regions. Fast spindle power (12-15Hz) was signifi-
cantly enhanced by so-tDCS in frontal (p < .001) and centroparietal 
(p =	 .041)	 regions.	Additionally	 slow	spindle	power	 (8–12	Hz)	was	
significantly increased after so-tDCS (p = .001). Analysis of phase 
amplitude coupling concluded that spindle power amplified during 
SO	up-phases	during	 so-tDCS	 leading	 to	 stronger	 synchronisation	
between	SO	and	spindle	power,	and	marginal	improvement	in	visual	
memory. So-tDCS was associated with a significantly greater pro-
portion	of	time	was	spent	in	NREM-2	(mean	difference	18.9%,	[95%	
CI	3.2–34.5],	p = .021), however no significant differences in sleep 
time or percentage of remaining sleep stages was found.
Melatonin
As well as begin studied in the context of optimising circadian 
rhythm, the effect of melatonin on NREM sleep was explored 
by Cruz-Aguilar et al. (2020) in a further analysis of data from the 
same study described in Cruz-Aguilar et al. (2018). Following me-
latonin administration, mean sleep latencies to all stages of NREM 
decreased significantly, NREMS-1: Placebo =	 36.63	min	SE	 [7.37],	
Melatonin =	 12.18	 min	 [SE	 1.07],	 t = 3.66, p = .008), NREMS-
2: Placebo =	 44.62	 min	 [SE	 8.03],	 Melatonin	 = 21.06 [SE 1.82], 
t = 2.86, p = .02, NREMS-3: Placebo =	 176.12	 min	 [SE	 6.28],	
Melatonin =	84.31	[SE	4.54],	t =	13.40,	p = <0.001. The study pro-
vided some support for the hypothesis that melatonin would be as-
sociated	with	increased	generation	and	coherence	of	slow	EEG	bands	
and	a	decrease	in	fast	EEG	band	relative	power	(RP)	and	coherence.	
Following adjustment for multiple comparison, during NREMS-2, a 
significant	increase	in	theta	band	(4–7	Hz)	RP	at	C3-A1	was	observed	
in the melatonin group (t =	−5.49,	p = .0009) along with a decrease 
in	gamma	band	(31–50	Hz)	F7-T3	and	F8-T4	interhemispheric	coher-
ence (t =	4.18,	p =	.0004).	During	NREMS-3,	a	significant	decrease	in	
beta	1	(14–19	Hz)	and	beta	2	(20–30	Hz)	RP	was	observed	at	C4-A2	
(t =	4.70,	p = .002) and (t = 3.62, p = .008) respectively. There was 
a	significant	 increase	 in	C3-A1	and	C4-A2	interhemispheric	coher-
ence of slow bands; delta (t =	−3.64,	p = .008) and theta (t =	−3.93,	
p = .005) but also of gamma (t =	−5.13,	p = .001) and a decrease in 
beta 1 coherence (t = 3.91, p = .005). There was also a decrease in 
all	EEG	band	F7-T3	and	F8-T4	 interhemispheric	 coherence	 follow-
ing melatonin administration. The authors conclude that shorter 
NREMS onset following melatonin administration in participants 
with	mild-moderate	AD	 is	 associated	with	 the	RP	and	EEG	coher-
ence differences described above and that these are likely to have 
been	achieved	 through	GABA-A	modulation	suggesting	 that	 these	
pathways may be well-preserved in this patient group.
3.6.4 | Treating co-morbidities
Continuous Positive Airway Pressure (CPAP)
Patients	with	Obstructive	Sleep	Apnoea	(OSA)	but	no	prior	diagno-
sis of a sleeping disorder and AD were recruited to a RCT by Cooke 
et al. (2009a). The effect of CPAP on sleep was compared with pla-
cebo CPAP using polysomnography. Those receiving therapeutic 
CPAP	after	one	single	night	had	significantly	decreased	Stage	I	sleep	
(p =	 .04)	and	significantly	 increased	Stage	2	Sleep	(p = .02). There 
were	no	changes	 in	%	REM,	Stage	III,	 IV	Sleep,	WASO,	SP,	TIB,	SE	
or	 SO	 in	 either	 group.	 Paired	 analysis	 after	 3	weeks	 showed	 that	
there	were	decreases	in	mean	WASO	(p =	.005),	TIB	(p = .002), SP 
(p < .001), Arousals per Hour (p =	.005)	and	%	Stage	I	Sleep	(p = .001) 
and	a	significant	 increase	 in	Stage	III	Sleep	(p =	 .006).	 In	summary	
CPAP was reported to deepen the level of sleep immediately and 
later lead to more consolidated sleep with fewer night-time awaken-
ings and improved SE.
Cooke et al. (2009b) also undertook analysis of the potential lon-
ger term effects of CPAP on sleep comparing 5 patients who had con-
tinued CPAP (CPAP+) following a previous randomized trial against 5 
patients	who	had	discontinued	CPAP	(CPAP−)	approximately	3	years	
after the initial study. The CPAP+ group were found to have a signif-
icant	statistical	improvement	in	PSQI	while	the	CPAP-	group	showed	
a statistical deterioration (effect size = 1.8, p < .05). At baseline nei-
ther CPAP +	 nor	CPAP−	 groups	 had	 evidence	of	 daytime	 somno-
lence as measured by the Epworth Sleepiness Scale (ESS). However 
at	 follow-up,	ESS	 in	 the	CPAP−	group	had	deteriorated	 in	keeping	
with significant daytime somnolence (effect size = 0.8) whilst ESS in 
the CPAP+ group remained stable compared to baseline.
3.6.5 | Bedtime routines
Aromatherapy (Aroma Oil as Bath Salt)
Kouzuki et al. (2020) conducted a randomised controlled trial of 
aroma oil as a bath salt, to determine its effect on cognition, olfac-
tory function and subjective measures of sleep as determined by 
PSQI-J	(Japanese	version	of	PSQI).	35	participants	with	MCI	or	AD	






A structured limbs-exercise program
Wang et al. (2020) conducted a randomised controlled trial of a 
structured	 limbs-exercise	 program	 in	 participants	 with	 MCI.	 The	
aim was to test for a predicted beneficial effect on cognitive func-
tion and to determine the presence and strength of mediating path-
ways including sleep. 116 participants were randomly assigned to 
an intervention group consisting of three 60 min structured limbs 
exercise	sessions	for	24	weeks	 (supervised	for	12	weeks	and	then	
unsupervised for the remaining 12 weeks) or health promotion 
classes	only.	PSQI	was	used	as	a	subjective	measure	of	sleep	qual-
ity. 111 participants completed the study following 5 exclusions. 
Total	PSQI	scores	were	non-significantly	 lower	 in	 the	 intervention	
group 12 weeks post baseline and subsequently significantly lower 
24	weeks	post	baseline	with	mean	difference	−2.45	[95%	CI	−3.509,	
−1.391],	p = .001. A corresponding decrease in depressive symptoms 
as	measured	by	 the	Geriatric	Depression	Scale	 (GDS)	was	also	 re-
ported	 in	 the	 intervention	group	with	 a	mean	difference	of	−1.64	
[95%	CI	−2.658,	−0.613],	p =	 .002.	In	further	analysis	of	mediating	
effects, sleep quality appeared more strongly related to general cog-
nitive function and had the greater mediating effect when compared 
to depressive symptoms.
3.6.7 | Treating psychological factors 
causing insomnia
Cognitive Behavioural Therapy – Insomnia (CBT-I)
Cassidy-Eagle et al. (2018a, 2018b) employed a two-arm RCT to 
explore	effects	of	CBT-I	 on	 a	 sample	of	28	participants	with	MCI	
and	a	DSM-IV	diagnosis	of	insomnia.	A	standard	CBT-I	protocol	over	
6	weeks	was	adapted	for	participants	with	MCI	through	a	reduction	
in content covered, inclusion of brief, focused rationales for treat-
ment, time allowed for review and repetition of content as well as re-
minder/	troubleshooting	calls	between	intervention	sessions.	It	was	
compared against an ‘Active Control Nutrition Class’ with identical 
in-person and phone contact hours which provided learning mod-
ules delivered by a dietician covering the impact of diet on aging. 
These adaptations to standard CBT were hypothesised to improve 
both objective actigraphy variables and self-reported insomnia 
symptoms	through	the	ISI.
CBT-I	was	shown	to	have	a	highly	significant	desirable	effect	on	
4	out	of	5	outcome	variables.	 ISI	 decreased	 from	15.29	 (SD 2.33) 
to 3.25 (SD 2.05) in the intervention group, SL from 11.03 (SD 
11.69) to 1.93 (SD	 3.57),	WASO	 from	104.24	 (SD	 38.21)	 to	46.95	
(SD	25.09)	and	SE	increased	from	0.792	(SD	0.0744)	to	0.8804	(SD 
0.0719).	Multilevel	 regression	analysis	revealed	these	outcomes	as	
statistically	significant	with	large	effect	sizes	ISI	(p < .001 Cohen's 
d2	−4.22),	SL	(p < .001 Cohen's d2	−1.73),	WASO	(p < .001 Cohen's 
d2	−2.32),	SE	(p < .001 Cohen's d2 1.89). TST, however, appeared to 
decrease	from	436.61	(SD	51.53)	to	379.50	(SD	75.13)	in	the	inter-
vention group, also finding statistical significance with a large effect 
size (p = .02 Cohen's d2	−2.32).
“Sleep Well – Think Well” Group Program
Naismith et al. (2018) evaluated the “Sleep Well – Think Well” 
Program	 in	 a	 pilot	 RCT	 of	 35	 participants	 with	 MCI	 but	 without	
underlying sleep disorders. The program involved provision of five 
booklets, specifically a relaxation booklet, anxiety and worry book-
let, healthy sleep practices and intervention booklet, mindfulness 
booklet and a booklet detailing helpful/ unhelpful thoughts associ-
ated with sleep initiation and maintenance to both active and con-
trol groups. The active intervention group received four face-to-face 
sessions consisting of psychoeducation, introduction of a guided 
individualised treatment plan, monitoring of the treatment plan and 
a summary and consolidation session. Fortnightly compliance moni-
toring telephone sessions were also conducted. The control group 
received fortnightly calls to discuss handbook content but no direc-
tive, supportive input as above.
There was evidence of improved subjective sleep through a 
statistically	 significant	 reduction	 of	 mean	 total	 PSQI	 score	 in	 the	
intervention	group	(Mean	change	−2.4	p = .023 Cohen's d = 0.83). 
Analysis	 of	 individual	 PSQI	 components	 showed	 statistically	 sig-
nificant improvement in SE (p =	 .049)	 and	 daytime	 dysfunction	




Comprehensive literature search revealed a relative paucity of ro-
bust data evaluating sleep interventions and their efficacy in a popu-
lation	with	mild	AD	or	MCI.	The	majority	of	studies	were	of	small	
scale	and	many	subject	to	potential	QA	limitations	and	bias.	In	all	of	
the potential theoretical domains for intervention (Figure 1), there 
are strategies that have not yet been tried. Additionally with the 
possible exception of the ‘Sleep Well, Think Well’ trial most studies 
focussed on one intervention as opposed to a multi-modal approach.
The largest trial in this review conducted by Herring et al. (2020) 
showed that the dual orexin receptor antagonist Suvorexant led 
to significant macro-architectural changes in sleep including an in-
crease	in	TST,	SE	and	a	reduction	in	WASO.	Of	note,	improvements	
in TST significantly favoured Suvorexant only in the subgroup with 
mild (21–26) MMSE scores and not in the moderate group, high-
lighting potential differences in treatment efficacy between these 
groups. However, increased rates of daytime somnolence and ad-
verse events may limit its potential adoption in this population.
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The	 most	 widely	 studied	 intervention	 were	 the	 AChEIs	 likely	
due to a combination of theoretical, clinical and pragmatic reasons. 
Early neurochemical theories of sleep hypothesised Acetylcholine 
playing	a	primary	role	in	wakefulness	and	REM	sleep	(Jouvet,	1972),	
further strengthened by later work underlying the muscarinic M2 
receptor's role in potentiating REM sleep (Baghdoyan & Lydic, 1999; 
Watson et al., 2012). Clinically, donepezil has been associated with 
vivid dreams and insomnia with higher incidences versus placebo 
reported in multiple studies (Burns et al., 1999; Pratt et al., 2002; 
Rogers et al., 1998) which alongside their common use in those with 
early cognitive impairment may have driven further research.
The results of trials included here did not reveal a consistent 
benefit	of	AChEIs	on	sleep	and	it	seems	unlikely	this	class	of	medi-
cations will be pursued further to benefit sleep. The one exception 
to this could involve new technology for drug delivery to modulate 
available acetylcholine to better mimic physiological fluctuations in 
cholinergic	 activity.	 Given	we	 know	 that	 cholinergic	 synapses	 are	
involved in learning while awake (Huerta & Lisman, 1993) and less 
so during sleep, perhaps more refined temporal target (e.g. daytime 
only) could improve nocturnal sleep and memory consolidation. We 
generally noted that there were no identified studies where a day-
time-only pharmacological intervention, promoting wakefulness or 
attention, was utilised as a tool to enhance night-time sleep, and this 
could be a useful future approach.
In	a	population	with	OSA	and	mild	AD/MCI,	CPAP	does	appear	to	
be an effective intervention with significant positive effects demon-
strated both in sleep architecture and key sleep parameters. Sleep 
apnoea affects a large proportion of people aged over 50 (Heinzer 
et al., 2015), therefore treating sleep apnoea holds great promise to 
improve quality of life and delay AD progression. Sleep apnoea is 
sufficiently common that screening should be a routine part of clin-
ical practice in memory clinics - we already know that patients can 
benefit through treatment of sleep apnoea regardless of whether 
they have AD. The possibility of treating AD is an added benefit. 
We also propose that screening and, if required, treatment of sleep 
apnoea should occur before entry into AD clinical trial of any type. 
Unless we exclude the impact of sleep apnoea on AD progression, 
we may be clouding benefit from other therapeutic approaches.
Two studies explored the effect of tailored psychotherapeutic 
programs designed on principles of Cognitive Behavioural Therapy. 
Outcomes	were	mixed,	with	Naismith	et	al.	(2018)	reporting	a	sub-
stantial improvement in subjective sleep quality but observing no 
significant	 change	 in	 objective	 actigraphy	 measures.	 In	 contrast,	
Cassidy-Eagle et al. (2018a, 2018b) reported significant improve-
ment	in	4	out	of	5	objective	outcome	measures	including	SL,	WASO	
and	SE	as	well	as	significant	improvements	in	subjective	quality	(ISI).	
Of	 note,	 however,	 there	 were	 potentially	 significant	 differences	
between the two populations with those recruited to the Cassidy-
Eagle	et	 al.	 (2018a,	2018b)	 study	 requiring	a	DSM-IV	diagnosis	of	
Insomnia	 in	contrast	 to	 the	Naismith	et	al.	 (2018)	 study.	Critically,	
both	studies	highlight	the	feasibility	of	this	approach	in	MCI.
Melatonin appeared to significantly reduce sleep latency both 
when	analysed	utilising	PSG	by	Cruz-Aguilar	et	al.	(2018)	and	utilising	
actigraphy by Jean-Louis et al. (1998) who also demonstrated a re-
duction in overnight transitions from sleep to wakefulness. Both 
studies were of small numbers however with 8 and 10 participants 
respectively.	Other	approaches	specific	to	circadian	rhythm	modifi-
cation have not been systematically explored despite evidence that 
circadian rhythms are disturbed in AD.
Three studies specifically explored interventions attempting 
to enhance the duration or characteristics of NREM sleep. Phase 
locked acoustic stimulation appeared to have no effect on basic 
sleep parameters or sleep-stage architecture but did appear to in-
crease	SWA	and	SO	whilst	‘ON’	without	increasing	its	mean	overall	
when compared to a sham comparison group. Similarly, transcranial 
stimulation	during	afternoon	naps	was	shown	to	increase	SO	power	
and fast spindle power whilst also enhancing their synchronisation 
with no significant effects on sleep-stage architecture. Melatonin 
reduced sleep latency to all stages of NREM and was associated with 
increased	generation	and	coherence	of	slow	EEG	bands	according	to	
Cruz-Aguilar et al. (2020).
A	 structured	 exercise	 program	 in	 participants	 with	 MCI	 was	
associated	 with	 a	 statistically	 significant	 reduction	 in	 PSQI	 score	
although	 there	was	a	corresponding	significant	decrease	 in	Global	
Depression Score raising questions as to causality direction. Further 
evidence is likely to arise from the currently recruiting Dementia-
MOVE	randomised	controlled	trial	(Haeger	et	al.,	2020).	This	intends	
to explore the effects of a long-term, 6 month, multicomponent ex-
ercise program on brain metabolism together with actigraphic and 
subjective measures of sleep in participants with early AD.
Overall,	aside	from	two	larger	trials,	the	studies	were	of	relatively	
small scale. The studies included also had differing aims in analysing 
sleep amongst which symptomatic relief of insomnia, macro and mi-
cro-architectural optimisation of sleep and sleep analysis as an ef-
fect mediator were found. The overall lack of available evidence was 
surprising given the broad range of pharmacological and non-phar-
macological sleep interventions available for use in the general 
population. Striking omissions include the most common group of 
pharmacological interventions for insomnia (Z-hypnotics such as zo-
piclone) which appear to have no evidence base in this group.
There were multiple interventions such as vitamin B12, risper-
idone, acupressure, bright light therapy, transcutaneous electric 
nerve stimulation (TENS) and music interventions that were not in-
cluded in our review either due to the use of unvalidated sleep out-




Lifestyle modification was explored only in the context of psy-
chotherapeutic	approaches	rather	than	in	isolation.	It	was	with	re-
gret that a high quality randomised controlled trial in individuals from 
a general community setting with reduced MoCA scores, testing the 
effects of a multimodal tailored lifestyle intervention in improving 
actigraphic and subjective measures of sleep (Falck et al., 2020) 
could not be included due to our pre-determined strict method-
ology regarding diagnostic criteria. The intervention consisted of 
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sleep hygiene measures followed by the formulation of an individ-
ually timed Bright Light Therapy and was shown to have improved 
measures of subjective but not objective sleep quality. Whilst in 
established mild-moderate AD dementia there are concerns about 
cognitive limitations that might prevent behavioural change, it is our 
belief that this type of tailored intervention may well be a fruitful 
route for further exploration, particularly given that cognitive func-
tion at this stage often still allows significant adaptation of lifestyle 
and motivation can be high. Furthermore, pharmacological interven-
tions are inherently associated with potential toxicity and the bur-
den of polypharmacy.
4.2 | Strengths and limitations
This is the first review we know of to focus on sleep intervention 
in	MCI	and	Mild	AD.	A	comprehensive	electronic	database	search	
protocol was performed with a wide range of potential sleep inter-
ventions sought. Additionally, we summarized findings on multiple 
dimensions of sleep outcome data. A process for rigorous justifica-
tion of all subsequent decisions in terms of inclusion/exclusion was 
utilised.	 As	 with	 the	 inclusion	 criteria	 for	 AD	 dementia/MCI,	 at-
tempts were made to contact authors in cases of ambiguity.
A significant challenge in this review was in formulating inclu-
sion criteria to ensure that studies involving important, clinically 
relevant interventions were included but also ensuring that stud-
ies with an overly heterogeneous population whose findings may 
not be applicable to our population of interest were excluded. A 
threshold	 of	 75%	was	 chosen	 for	 participants	 to	 have	 an	 estab-
lished	diagnosis	of	AD	dementia	or	MCI.	It	was	further	decided	to	
exclude any study where the majority of participants have moder-
ate or severe dementia. Naturally these cut-offs could be criticised 
either for diluting the population of interest or for failing to allow 
for inclusion of relevant studies. We therefore cannot exclude the 
possibility that there may be important findings left unreported. 
Included	studies	reported	on	a	range	of	diverse	outcomes,	which	
whilst individually valid, made comparison across studies challeng-
ing. Direct comparison was further hindered by variations in study 
designs permitting or excluding the presence of underlying rec-
ognised	 sleep	 disorders	 amongst	 participants.	 Ideally,	 the	 effect	
of interventions on specific sleep phenotypes would have been re-
viewed, however unfortunately this information was not reported 
on the scale to allow for meaningful comparison. Nonetheless our 
decision to include studies regardless of phenotype could be ar-
gued to increase real-world applicability to the clinical population 
and is not contrary to the central hypothesis that an improvement 
in sleep regardless of baseline may positively impact on AD pro-
gression. Quality appraisal scores across included studies were 
variable and with one exception, those included were largely sub-
ject to at least one domain of significant bias thereby potentially 
compromising their findings. This though, remains consistent with 
our assertion that there is a paucity of reliable, large-scale data for 
this population. For this present review, the risk of publication and 
language bias for current literature is also recognised.
4.3 | Clinical implications and future direction
The lack of rigorous evidence presents a significant future research 
demand.	Those	with	MCI	and	mild	AD	might	not	respond	identically	
to interventions with more robust evidence in the general popula-
tion or in those with severe AD dementia. Sleep disturbance may 
well play a role in triggering or facilitating pathophysiology in AD 
and is the subject of current, ongoing research. Finding evidence-
based treatments for sleep disturbance in a population before more 
severe manifestations of AD dementia develop, may therefore even 
offer the potential to delay the onset of more significant functional 
impairment.	Of	 note,	 the	 included	 studies	 had	 a	 diversity	 of	 aims	
including symptomatic relief of insomnia, optimisation of macro or 
micro-architectural sleep parameters and assessing sleep distur-
bance	as	an	effect	mediator	for	cognitive	impairment.	In	the	future,	
a more standardised set of outcome criteria may be helpful in allow-
ing efficacy of interventions to be more meaningfully and directly 
compared. As understanding develops of the precise mechanisms 
by which sleep contributes to the progression of AD pathology, this 
may occur naturally.
5  | CONCLUSION
In	 the	 specific	 population	 of	MCI	 and	mild	 AD	 there	 is	 a	 relative	
paucity of evidence available in supporting efficacious interventions 
for sleep disturbance, nonetheless positive outcomes have been 
reported. Psychotherapeutic approaches utilising adapted CBT, 
melatonin,	suvorexant	and	CPAP	for	OSA	all	hold	promise.	Acoustic	
stimulation and transcranial stimulation significantly affect specific 
micro-architectural characteristics of NREM sleep, the long-term 
cognitive and disease modifying effects of which can be theorised 
but	 are	 not	 known.	 In	 our	 opinion,	 given	 the	wide	 health	 risks	 of	
OSA,	screening	should	become	routine	 in	memory	clinics.	Despite	
behavioural interventions often being low cost and non-toxic, we 
found remarkably little work in this domain. This review identifies a 
significant need to explore multiple, alternative sleep interventions 
through high quality, comparison experimental studies utilising vali-
dated sleep outcome measures.
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